Welcome to our dedicated page for Esquire Financial Holdings SEC filings (Ticker: ESQ), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Esquire Financial Holdings's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Esquire Financial Holdings's regulatory disclosures and financial reporting.
Esquire Financial Holdings, Inc. reported that one of its directors received a grant of 753 shares of restricted common stock on December 10, 2025, at a stated price of $0 per share. These restricted shares are scheduled to vest 100% on December 10, 2026.
After this grant, the reporting person beneficially owns 59,400 shares of common stock, including multiple prior restricted stock awards that vest in annual installments from December 19, 2023 through December 15, 2027. The director also holds 1,500 fully vested stock options with an exercise price of $24.9 per share, expiring on December 10, 2028.
Esquire Financial Holdings, Inc. disclosed that one of its directors acquired 753 shares of restricted common stock on December 10, 2025 at a price of $0 per share. These restricted shares vest 100% on December 10, 2026.
Following this award, the director beneficially owns 15,716 shares of common stock directly, along with indirect holdings of 25,500 shares as trustee for a trust, 12,600 shares through a limited partnership, 79,033 shares through another trust, and 21,001 shares through a profit sharing plan. The filing notes that these totals include multiple restricted stock grants scheduled to vest in three equal annual installments beginning on various dates between December 19, 2023 and December 15, 2027.
Esquire Financial Holdings, Inc. reported that one of its directors acquired 753 shares of common stock on December 10, 2025 at a price of $0, reflecting a grant of restricted stock.
These 753 restricted shares vest 100% on December 10, 2026. Following this award, the director beneficially owns 4,436 common shares directly and also holds 9,786 shares indirectly through an LLC II, 6,000 shares indirectly through the director's mother, and 127,531 shares indirectly through an LLC I, including restricted stock scheduled to vest in three equal annual installments beginning in 2026 and 2027.
Esquire Financial Holdings, Inc. reported an insider equity award by one of its directors. On 12/10/2025, the director acquired 1,836 shares of common stock as restricted stock at a price of $0. These restricted shares vest 100% on December 10, 2026.
Following this grant, the director beneficially owns 49,267 shares of common stock directly, 12,910 shares indirectly through a trust, and 36,000 shares indirectly through an IRA. The director also holds fully vested stock options covering 20,000 shares of common stock with an exercise price of $12.5 per share, expiring on 09/01/2026.
Esquire Financial Holdings, Inc. director reported acquiring 753 shares of restricted common stock on December 10, 2025 at a stated price of $0 per share. Following this grant, the director beneficially owns 72,401 shares of common stock directly.
The newly reported 753 restricted shares vest 100% on December 10, 2026. The total holding includes multiple prior restricted stock awards that vest in three equal annual installments beginning on December 19, 2023, December 9, 2025, December 19, 2026, December 3, 2027, and December 15, 2027. The director also holds fully vested stock options for 2,000 shares at $20.85 expiring December 16, 2030 and 1,750 shares at $31.04 expiring December 9, 2031.
Esquire Financial Holdings, Inc. disclosed that one of its directors received a grant of 753 shares of restricted common stock on December 10, 2025. The shares were awarded at $0 per share and are scheduled to vest 100% on December 10, 2026.
After this grant, the director beneficially owns 142,679 shares of common stock directly, which include multiple restricted stock awards that vest in three equal annual installments beginning on dates between December 19, 2023 and December 15, 2027. In addition, the director indirectly owns 2,500 shares through an insurance trust I and 2,500 shares through an insurance trust II.
Esquire Financial Holdings, Inc. disclosed that one of its directors acquired 753 shares of restricted common stock on December 10, 2025 at a stated price of $0 as a restricted stock award. After this transaction, the director beneficially owns 2,620 shares of common stock in direct ownership.
The 753 restricted shares are scheduled to vest 100% on December 10, 2026. The reported holdings also include additional restricted stock that will vest in three equal annual installments beginning on December 3, 2027.
Esquire Financial Holdings, Inc. reported an insider equity award involving one of its directors. On December 10, 2025, the director acquired 753 shares of common stock in a transaction reported with code "A" at a stated price of $0, indicating a grant rather than an open-market purchase.
These shares are described as restricted stock that will vest 100% on December 10, 2026. Following this transaction, the director beneficially owned 753 shares, held as direct ownership. The filing is made by a single reporting person in their capacity as a director.
Esquire Financial Holdings, Inc. reported that one of its directors acquired 753 shares of common stock as a restricted stock award on December 10, 2025, at a price of $0. These restricted shares vest 100% on December 10, 2026. Following this grant, the director beneficially owns 87,352 shares directly, plus 48,000 shares held indirectly as trustee for trusts and 12,000 shares held indirectly as custodian for children. The director also holds fully vested stock options covering 584 shares of common stock with an exercise price of $31.04, exercisable since December 9, 2022 and expiring on December 9, 2031.
Esquire Financial Holdings, Inc.'s senior vice president and chief financial officer reported a transaction in the company's common stock dated December 9, 2025. The filing shows a disposition of 300 shares of common stock, coded "F", at a price of $104.04 per share.
After this transaction, the officer beneficially owns 18,612 shares of common stock directly, which include restricted stock awards vesting in three equal annual installments commencing on December 19, 2023, December 16, 2024, December 9, 2025, December 19, 2026, December 15, 2027, and January 30, 2028, and 1,500 shares indirectly through an IRA. The officer also holds stock options covering 1,500 shares at an exercise price of $24.9 and four grants of 2,500 shares each at exercise prices of $20.85, $31.04, $42.3, and $48.32, with expiration dates on December 10, 2028, December 16, 2030, December 9, 2031, December 19, 2032, and December 15, 2033.